Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | Zendy

Raphael Brandão Moreira | Zendy; Márcio Debiasi | Zendy; Edoardo Francini | Zendy; Pier Vitale Nuzzo | Zendy; Guillermo de Velasco | Zendy; Fernando Cotait Maluf | Zendy; André P. Fay | Zendy; Joaquim Bellmunt | Zendy; Toni K. Choueiri | Zendy; Fabio A.B. Schutz | Zendy

Open Access

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

Author(s) -

Raphael Brandão Moreira,

Márcio Debiasi,

Edoardo Francini,

Pier Vitale Nuzzo,

Guillermo de Velasco,

Fernando Cotait Maluf,

André P. Fay,

Joaquim Bellmunt,

Toni K. Choueiri,

Fabio A.B. Schutz

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.20028

Subject(s) - enzalutamide , medicine , meta analysis , randomized controlled trial , abiraterone , pharmacology , oncology , prostate cancer , androgen receptor , cancer

Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized controlled trials (RCT) to better characterize the risk of adverse events associated with both drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research